Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 65,244 |
|
|||||
| News | (1) | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Mustang Bio Inc | MBIO | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.003 | 1.27% | 0.24 | 07:54:07 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.237 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 127 | 65,244 | - | 0.22 - 8.17 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 07:54:07 | formt | 100 | US$ 0.24 | USD |
Mustang Bio Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 2.49M | 10.39M | - | 0 | -51.6M | -4.97 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Mustang Bio News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MBIO Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.35 | 0.3699 | 0.22 | 0.2809108 | 263,030 | -0.11 | -31.43% |
| 1 Month | 1.02 | 1.03 | 0.22 | 0.468084 | 301,998 | -0.78 | -76.47% |
| 3 Months | 1.34 | 1.49 | 0.22 | 0.9122745 | 238,822 | -1.10 | -82.09% |
| 6 Months | 1.50 | 1.969 | 0.22 | 1.04 | 145,556 | -1.26 | -84.00% |
| 1 Year | 4.24 | 8.17 | 0.22 | 1.79 | 103,083 | -4.00 | -94.34% |
| 3 Years | 48.45 | 60.90 | 0.22 | 25.84 | 627,297 | -48.21 | -99.50% |
| 5 Years | 59.70 | 89.70 | 0.22 | 41.39 | 842,413 | -59.46 | -99.60% |
Mustang Bio Description
| Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies and CAR T therapies for solid tumors. |
